Resources for You
Emend (fosaprepitant dimeglumine) for Injection, 115 mg/mL February 2009
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- February 2009
|The detailed view includes drug products with safety labeling changes to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, or PATIENT PACKAGE INSERT/MEDICATION GUIDE sections. Deletions or editorial revisions made to these sections are not included in this summary. Read about the new physician labeling format.|
- Post-Marketing Experience
- pruritus, rash, urticaria; hypersensitivity reactions including anaphylactic reactions
PATIENT PACKAGE INSERT
- What are the possible side effects of EMEND?